Saint Luke’s Mid America Heart Institute offers the most comprehensive heart and vascular care in Kansas City. We provide the full range of cardiovascular services, from disease prevention to heart transplantation. At Saint Luke’s we use the latest technology to provide a full range of services and treatments. 

We provide:

  • More specialized physicians
  • More experience
  • More innovative treatment options for patients

Saint Luke’s Hospital is proud to be the third hospital in the U.S to achieve Comprehensive Cardiac Center certification from The Joint Commission. In 2023, we completed our 1,000th heart transplant, making us one of only 23 programs in the country to achieve this milestone. 

Services

Research and Clinical Trials

Cardiovascular research continues to be a major focus at Saint Luke’s Health System. The program currently encompasses research programs in each of the major clinical areas, including interventional cardiology, cardiac surgery, heart failure and cardiac transplantation, cardiac electrophysiology, cardiac imaging, and preventive cardiology/lipid and diabetes management.

In addition to supporting clinical research, the cardiovascular research program encompasses centers of excellence and core laboratories in:

  • Cardiovascular outcomes research
  • Health economics and technology assessment
  • Intravascular imaging
  • Noninvasive imaging

These centers of excellence currently serve as core laboratories for a wide range of studies that often involve collaboration with other leading cardiovascular centers and researchers from around the world. MAHI continues to serve as one of the four Analytic Centers, along with Duke, Harvard, and Yale, for the American College of Cardiology’s National Cardiovascular Data Registry.

Saint Luke's Mid America Heart Institute

Saint Luke's Mid America Heart Institute

4401 Wornall Rd
Kansas City, MO 64111 

Saint Luke's News

Dec. 19, 2024

Higher Omega-3 Levels Associated with Improved Cardiovascular Outcomes

According to a new study, higher omega-3 levels significantly reduce the risk of heart failure and heart failure fatalities.
Nov. 21, 2024

Healio: Potassium Binder Helps Optimize Spironolactone Use in Patients with HF, Hyperkalemia Risk

A potassium binder helped patients with heart failure who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk.
Nov. 19, 2024

KSHB: Saint Luke's Leads Groundbreaking AFib Treatment

Dr. Sanjaya Gupta spoke to KSHB about pulsed field ablation, as well as the second Saint Luke's patient to undergo this innovative new procedure to treat AFib.